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Protein Alpha, Cause Autosomal-Dominant
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Autosomal-dominant adult-onset neuronal ceroid lipofuscinosis (ANCL) is characterized by accumulation of autofluorescent storage
material in neural tissues and neurodegeneration and has an age of onset in the third decade of life or later. The genetic and molecular
basis of the disease has remained unknown for many years. We carried out linkage mapping, gene-expression analysis, exome
sequencing, and candidate-gene sequencing in affected individuals from 20 families and/or individuals with simplex cases; we identi-
fied in five individuals one of two disease-causing mutations, c.346_348delCTC and c.344T>G, in DNAJC5 encoding cysteine-string
protein alpha (CSPa). These mutations—causing a deletion, p.Leu116del, and an amino acid exchange, p.Leu115Arg, respectively—
are located within the cysteine-string domain of the protein and affect both palmitoylation-dependent sorting and the amount of
CSPa in neuronal cells. The resulting depletion of functional CSPamight cause in parallel the presynaptic dysfunction and the progres-
sive neurodegeneration observed in affected individuals and lysosomal accumulation of misfolded and proteolysis-resistant proteins in
the form of characteristic ceroid deposits in neurons. Our work represents an important step in the genetic dissection of a genetically
heterogeneous group of ANCLs. It also confirms a neuroprotective role for CSPa in humans and demonstrates the need for detailed
investigation of CSPa in the neuronal ceroid lipofuscinoses and other neurodegenerative diseases presenting with neuronal protein
aggregation.Introduction
The neuronal ceroid lipofuscinoses (NCLs) are a heteroge-
neous group of inherited neurodegenerative disorders
with an incidence of between 1 and 30 per 100,000. Com-
mon findings in the NCLs are an accumulation of auto-
fluorescent storage material in neural and peripheral
tissues and neurodegeneration. Although mutations in
eight genes—CLN1 (PPT1 [MIM 256730]), CLN2 (TPP1
[MIM 204500]), CLN3 (MIM 204200), CLN5 (MIM
256731), CLN6 (MIM 601780), CLN7 (MFSD8 [MIM
610951]), CLN8 (MIM 600143), and CLN10 (CTSD [MIM
610127])—have been identified in autosomal-recessive
childhood and juvenile NCLs1 and recently also in auto-
somal-recessive adult-onset NCL (Kufs disease [MIM
204300])2, the genetic and molecular basis of adult-onset
NCL with dominant inheritance (Parry type [MIM
162350]) remains unknown.
Autosomal-dominant adult-onset neuronal ceroid lipo-
fuscinosis (ANCL) was first described in a family of British
descent from New Jersey, USA (Parry disease),3 and in
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The AmericAmerican family with English ancestry (UCL563 in this
study),5 another family from Alabama, USA (UCL562),6,7
and a third family from the Netherlands (N1)8 were pre-
sented. Common characteristics of affected individuals
included generalized seizures, movement disorders, cogni-
tive deterioration, and progressive dementia; the age of
onset varied between 25 and 46 years.
In this work we describe a Czech family (P1) with auto-
somal-dominant ANCL in whom, by using a combination
of linkage mapping, gene-expression analysis, and exome
sequencing, we identified a unique heterozygous muta-
tion in DNAJC5 encoding cysteine-string protein alpha
(CSPa [MIM 611203]; information on CSPa is accessible
in the National Center for Biotechnology Information
[NCBI] Gene Entrez database under GeneID 54968). The
same or a second heterozygous DNAJC5 mutation was
found in four additional unrelated ANCL families that,
together with altered palmitoylation-dependent sorting
of mutant proteins in a cellular model and a reduced
amount of CSPa in neuronal cells of affected individuals,
confirmed the causality of CSPa mutations in autosomal-
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Material and Methods
Subjects
The Czech family (P1) was ascertained at the Institute of Inherited
Metabolic Disorders in Prague. Some families were described
earlier—an American family from USA with English ancestry
UCL563,5 a family from Alabama, USA (UCL562),6,7 and one
from the Netherlands (N1)8. Previously unpublished data from
families from the USA, France, the Netherlands, Belgium, Poland,
Austria, Italy, and Germany were collected under the auspices of
the Rare NCL Gene Consortium by Sara Mole. Enzyme assay or
analysis of known genes in which mutations lead to NCL had
excluded thesemutations as the cause in some but not all subjects.
Diagnosis of ANCL disease is very challenging, partly because of its
rarity but also because for some cases it can only be verified by
finding the characteristic pathology in the brain, and not all
affected individuals undergo this procedure. The cases included
here were diagnosed by clinicians in different countries over two
decades. Because full documentation was not always accessible,
some medical histories could not be reviewed. However, we chose
to test as many likely cases as possible and to fully report negative
findings. Investigations were approved by participating centers’
institutional review boards and were conducted according to the
Declaration of Helsinki principles. Written, informed consent
was obtained from all subjects.Genotyping and Linkage Analysis
Genomic DNA was isolated by standard technology. We geno-
typed DNA samples by using Affymetrix GeneChip Mapping
10K 2.0 arrays (Affymetrix, Santa Clara, CA) according to the
manufacturer’s protocol at the microarray core facility of the Insti-
tute of Molecular Genetics in Prague. We extracted raw feature
intensities from the Affymetrix GeneChip Scanner 3000 7G
images by using the GeneChip operating Software (GCOS) 1.4
and generated individual SNP calls by using Affymetrix Genotyp-
ing Analysis Software (GTYPE) 4.1.
We carried out multipoint parametric linkage analysis along
with a determination of the most likely haplotypes by using
affected-only analysis under the assumption of an autosomal-
dominant mode of inheritance with a 0.99 constant, age-indepen-
dent penetrance, 0.01 phenocopy rate, and 0.001 frequency of
disease allele; the analysis was performed with version 1.1.2 of
Merlin software.9 The results were visualized in the version
1.032 of the HaploPainter software10 and in version 2.9.2 of
R-project statistical software.Gene-Expression Analysis
We isolated leucocytes from freshly drawn blood by using a stan-
dard erythrocyte lysis protocol and isolated total RNA from freshly
isolated cells by using TRIZOL solution (Invitrogen, Carlsbad, CA).
RNA concentration was determined spectrophotometrically at
A260 nm by NanoDrop (NanoDrop Technologies), and quality
was checked on an Agilent 2100 Bioanalyser (Agilent Technolo-
gies). Aliquots of isolated RNA were stored at –80C until analysis.
Expression analysis was performed on the Illumina HumanRef-
8_V2 BeadChip at the microarray core facility of the Institute of
Molecular Genetics in Prague. Hybridized slides were scanned on
an Illumina BeadArray Reader, and bead level data were summa-
rized by Illumina BeadStudio Software v3. Bead summary data
were imported into R-project statistical software v.2.9.2 and
normalized with the quantile method in the Lumi package. Differ-242 The American Journal of Human Genetics 89, 241–252, August 1ential gene-expression analysis was performed with the Limma
package and the lmFit function. A multiple testing correction
was performed with the Benjamini and Hochberg method. Data-
base for Annotation, Visualization and Integrated Discovery
version 6.7 (DAVID) was used for functional annotation. Details
on the experiment and raw expression data are available at the
Gene Expression Omnibus (GEO) repository under accession
GSE30369.Copy-Number Analysis
DNA samples from seven individuals of family P1 (II.2, IV.1, IV.2,
IV.3, IV.4, IV.7, and IV.8) were genotyped with Affymetrix Gene-
Chip Mapping 6.0 array (Affymetrix, Santa Clara, CA) at the mi-
croarray core facility of the Institute of Molecular Genetics in
Prague according to the manufacturer’s protocol. Raw feature
intensities were extracted from the Affymetrix GeneChip Scanner
3000 7G images with the GeneChip Control Console Software
2.01. We generated individual SNP calls by using Affymetrix Gen-
otyping Console Software 3.02. Copy-number changes were iden-
tified in Affymetrix Genotyping Console Software (GTC version
3.02). We used data from both SNP and copy-number probes to
identify copy-number aberrations relative to a built-in reference.
Only regions larger than 10 Kb and containing at least five probes
were reported.Exome Sequencing
We performed DNA enrichment by using 3 mg of DNA from indi-
vidual IV.7 and the SureSelect All Exome kit (Agilent, Santa Clara,
USA) according to the manufacturer’s protocol. DNA sequencing
was performed on the captured DNA library with one-quarter of
a SOLiD 4 slide (Applied Biosystems, Carlsbad, USA) at CeGaT
(Tubingen, Germany). We aligned reads in color space to the refer-
ence genome (hg19) by using NovoalignCS version 1.01 (Novo-
craft, Malaysia) with the default parameters. Sequence variants
in the analyzed sample were identified with the SAMtools package
(version 0.1.8).11 The high-confidence variants list (SNP quality >
100 and indel quality > 50) was annotated with the SeattleSeq
Annotation server (hg19). Sequence variants that were not anno-
tated in the dbSNP or 1000 Genomes databases were prioritized
for further analysis.DNA Sequencing and Mutation Analysis
All exons and corresponding exon-intron boundaries of DNAJC5
(NM_025219.2), encoding CSPa, were amplified by PCR from
genomic DNA of the probands and sequenced with version 3.1
Dye Terminator cycle sequencing kit (Applied Biosystems, Foster
City, CA) with electrophoresis on an ABI 3500XL Avant Genetic
Analyzer (Applied Biosystems). Data were analyzed with Sequenc-
ing Analysis software. Segregation of the candidate mutations
was assessed by PCR and direct sequencing of the corresponding
genomic DNA fragments. Primer sequences are available in Table
S1, available online.Homozygosity-Haplotype Analysis
DNAJC5 genomic fragments containing multiple SNPs with high-
heterozygosity values were amplified by PCR from genomic DNA
of probands and sequenced as described above. Genotypes for
individual SNPs were obtained, and homozygous haplotypes
were defined as described recently.12 We compared the resulting
homozygous haplotypes across individuals to determine whether2, 2011
the chromosomal segments around the same identified mutations
could be identical by descent.
Bioinformatic Analysis of the Cysteine-String Domain
Hydrophobicity of the wild-type and mutant cysteine-string
domains were analyzed with a Kyte-Doolittle algorithm available
at Expasy server. Potential effects of detected mutations on CSPa
palmitoylation were assessed with the prediction program CSS-
Palm 2.0. Obtained hydrophobicity values and palmitoylation
score values were exported for each of the sequences and plotted
with an Excel function. We assessed possible impacts of the
p.Leu115Arg substitution on the structure and function of CSPa
by using SIFT and PolyPhen-2 servers.
CSPa-Expression Vectors
DNAJC5/CSPa cDNAwere amplified by RT-PCR from a control and
an affected individuals’ leucocytes with primers incorporating
a BspEI site at the 50 end of PCR products. Resulting PCR products
were first cloned into pCR4 TOPO vector (Invitrogen) and, after
sequencing verification, these were further subcloned in frame
into a pEGFP-C1 vector with BspEI and ApaI restriction sites.
The initiating methionine codon was removed from DNAJC5/
CSPa in all enhanced green fluorescent protein (EGFP)-CSPa
constructs.
Transient Expression of EGFP-CSPa
pEGFP-CSPa constructs were transfected into CAD-2A2D5 (CAD5)
cells derived from Cath.a-differentiated (CAD) cells (provided by
Sukhvir Mahal, The Scripps Research Institute, Jupiter, FL, USA).
One day before transfection, 8 3 104 cells/cm2 were seeded with
OptiMEM medium (OptiMEM; Invitrogen) containing 9% BGS
(HyClone, Logan, UT), 90 units penicillin/ml, and 90 g of
streptomycin/ml. Cells were transfected by either 0.8 mg or
4.5 mg of plasmid constructs with Lipofectamine 2000 (Invitrogen)
in serum and antibiotics free OptiMEM medium according to the
manufacturer’s protocol. Transfection experiments were per-
formed in more than five replicates.
Immunofluorescence Analysis
Cells were fixed 24 hr after transfection with 4% paraformalde-
hyde, permeabilized in 0.1% TRITON, washed, blocked with 5%
bovine serum albumin (BSA), and incubated for 1 hr at 37C
with anti-protein disulfide isomerase (PDI) mouse monoclonal
IgG1 (Stressgen, San Diego, CA) for endoplasmic reticulum (ER)
localization, anti-GS28 mouse IgG1 (Stressgen, San Diego, CA)
for Golgi localization, and anti-GFP rabbit polyclonal IgG (Abcam)
for EGFP-CSPa detection. For fluorescence detection, correspond-
ing species-specific secondary antibodies Alexa Fluor 488 and
Alexa Fluor 555 (Molecular Probes, Invitrogen, Paisley, UK) were
used. Nuclei were stained with 4’,6-diamidino-2-phenylindole
(DAPI). Prepared slides were mounted in fluorescence mounting
medium Immu-Mount (Shandon Lipshaw, Pittsburgh, PA) and
analyzed by confocal microscopy.
Image Acquisition and Analysis
XYZ images sampled according to Nyquist criterion were acquired
with a TE2000E C1si laser scanning confocal microscope, a Nikon
PlanApo objective (403, N.A.1.30), 488 nm and 543 nm laser
lines, and 5155 15 nm and 5905 15 nmband-pass filters. Images
were deconvolved with the classic maximum likelihood restora-
tion algorithm in Huygens Professional software (SVI, Hilversum,The AmericThe Netherlands).13 Colocalization maps employing single pixel
overlap coefficient values ranging from 0–114 were created with
Huygens Professional software. The resulting overlap coefficient
values are presented as pseudocolor (the scale is shown in the
corresponding lookup tables).Immunoblot Analysis
Transfected CAD5 Cells
Cells were harvested in PBS; centrifuged at 500 g for 7 min; and
resuspended in 10 mM Tris, 10 mM KCl, 2 mM EDTA, 4% glycerol,
1 mM DTT, and Complete Protease Inhibitor Cocktail (Roche);
homogenized by sonication followed by centrifugation at 20,000 g
for 15 min at 4C; and assessed for protein content in the superna-
tant with the Bradford assay.
Brain Homogenates
Frozen autopsy materials were homogenized under liquid ni-
trogen; dissolved in 10mMTris, 10mMKCl, 2mMEDTA, 4% glyc-
erol, 1 mM DTT, and Complete Protease Inhibitor Cocktail
(Roche); centrifuged at 20,000 g for 15 min at 4C; and assessed
for protein content in the supernatant with the Bradford assay.
Homogenate aliquots corresponding to 30 mg of total protein in
brain homogenates or 20 mg of total protein in CAD5 cells were
resolved on 12% SDS-PAGE under nonreducing or reducing condi-
tions and transferred to the polyvinylidene fluoride (PVDF) mem-
brane. Membranes were blocked by 5% BSA and 0.05% Tween 20
in PBS. CSPa or CSPa-EGFP protein was visualized by incubation
with rabbit CSP antibody (Stressgen) at 1: 500 in 5% BSA and
0.05%Tween 20 in PBS for 90min or rabbit GFP antibody (Abcam)
at 1:5000 in 5% BSA and 0.05% Tween 20 in PBS for 90 min,
followed by incubation with goat anti-rabbit HRP (Pierce) at
1:10000 in 0.05% Tween 20 in PBS for 60 min and detection by
SuperSignal West Femto Maximum Sensitivity Substrate (Pierce).
For depalmitoylation studies, samples were depalmitoylated prior
to SDS-PAGE by treatment with neutral 1M hydroxylamine or 1M
Tris as a control for 20 hr at room temperature.Immunohistochemical and Histochemical Studies
Formaldehyde-fixed brain samples were analyzed. Immunodetec-
tion of CSPa on paraffin sections was performed with rabbit CSP
antibody (Stressgen; diluted 1:750 in 5% BSA) in PBS. Synaptic
regions were detected with monoclonal mouse IgG1 synaptobre-
vin antibody (Sigma, Saint Louis, USA; diluted 1:8000 in 5%
BSA) in PBS, which was applied after heat-induced epitope
retrieval at pH 6.0. Detection of the bound primary antibody
was achieved with Dako EnVision þ TM Peroxidase Rabbit kit
(Dako, Glostrup, Denmark) with 3,30-diaminobenzidine as sub-
strate. The specificity of the antigen detection was always ascer-
tained by omitting of the primary antibody-binding step.
Stored ceroid material was best detected because of its promi-
nent autofluorescence via filter block with an excitation wave-
length of 400–440 nm (fluorescence microscope Nikon E800, filter
block BV-2A).Results
Clinical Observations and Biochemical Findings
The diagnosis of ANCL in family P1 (Figure 1A) was based
on clinical presentation and examination of proband III.6,
who presented at age 30 with myoclonic epilepsy, gen-
eralized tonic-clonic seizures, and progressive cognitivean Journal of Human Genetics 89, 241–252, August 12, 2011 243
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Figure 1. Pedigree and Neuropathology Findings in Family P1
(A) Pedigree of the Czech family. Black symbols denote affected individuals; open symbols denote unaffected individuals. Age of onset is
shown above current age or age of death (indicated by y).
(B) Epifluorescence. Hippocampal pyramidal neurons with prominent lysosomal storage of autofluorescent material representing the
general neurolysosomal storage pattern in the brain cortex. The autofluorescence was demonstrated with the filter block with an
excitation wavelength of 400–440 nm.
(C) Electron micrograph. GROD-type ultrastructure of the storage lysosomes.deterioration with depression; these symptoms were
followed by progressive motor neurological symptoms
leading to death at age 37 years. There was normal activity
of palmitoyl-protein-thioesterase 1 (PPT1) in leucocytes.
Neuropathological examination of postmortem brain tis-
sue showed characteristic neurolysosomal storage of auto-
fluorescent material with ultrastructural appearance
corresponding to granular osmiophilic deposits (GRODs)
(Figures 1B and 1C). A skin biopsy was free of lysosomal
storage at the ultrastructural level. An affected status in
other family members was assigned if a very similar clinical
course starting with myoclonic and/or generalized tonic-
clonic seizures followed after 1–2 years by progressive
cognitive deterioration and depressive symptomatology.
All affected individuals showed generalized epileptic dis-
charges in electroencephalograms and manifested brain-
stem and central pyramidal neurological symptomatology
in the later period of disease. Other ANCL families ana-
lyzed in this study are described in Table 1. Previously
unpublished families and cases with mutation in CSPa
are described in more detail below.
The proband of family UCL328 was a male of European
descent and in good health until his first generalized tonic-
clonic seizure at age 34. This was followed by evidence of
progressive confusion and dementia as well as more fre-
quent, medically refractory generalized seizures. Long-
term electroencephalography showed generalized periodic
epileptiform discharges superimposed on a background of
diffuse low-amplitude, high-frequency activity consistent
with a dementing process. A brain MRI at age 38 showed
prominence of cortical sulci and cerebellar folds and mild
enlargement of the lateral ventricles consistent with
diffuse cerebral and cerebellar atrophy. Concurrent neuro-
psychiatric testing showed a verbal IQ of 77, a performance
IQ of 71, and a full-scale IQ of 73. Regression of gross and
fine motor skills began at age 40, and there was ensuing244 The American Journal of Human Genetics 89, 241–252, August 1evidence of ataxia and myoclonus. By age 45, the proband
was wheelchair-bound and required nursing-home care.
Visual function was normal. A frontal lobe brain biopsy re-
vealed numerous neurons containing homogeneous eosin-
ophilic material with a golden-brown hue. The pigmented
material stained intensely by the periodic acid-Schiff reac-
tion and was found to be autofluorescent. Ultrastructural
examination showed multiple neurons distended by gran-
ular osmiophilic deposits. There was no family history of
seizures, early-onset dementia, or other neurologic abnor-
mality.
The proband of family UCL519 is one of at least five
similarly affected individuals over three generations with
apparent autosomal-dominant inheritance. He showed
obsessive behavior starting in his mid-20s, and the first
seizure occurred when he was in his early 30s. His speech
regressed, his short-term memory became impaired, and
he had difficulty in walking without an aid. No further
details are available.
Identification of CSPa Mutation in Family P1
by a Combination of Linkage Analysis,
Copy-Number Analysis, Gene-Expression
Analysis, and Exome Sequencing
To map the disease locus, we used Affymetrix GeneChip
Mapping 10K v2.0 arrays, genotyped all available and
informative family members, and performed linkage anal-
ysis. We identified five candidate regions with positive
LOD scores on chromosomes 1, 4, 15, 20, and 22 (Fig-
ure 2A). In parallel, we used Affymetrix GeneChip Map-
ping 6.0 array, genotyped seven individuals, and assessed
copy-number changes; we found no indication for a poten-
tially disease-causing deletion or duplication.
To identify a mutation that affected the amount of tran-
script, we compared gene-expression profiles in leucocytes
isolated from four affected individuals to those from four2, 2011
Table 1. ANCL Families Analyzed in This Study
Family No. Mutation in CSPa Country Diagnosis References
P1 p.Leu116del Czech Republic ANCL, autosomal dominant
N1 p.Leu115Arg The Netherlands ANCL, autosomal dominant 8,31,32
UCL563 p.Leu115Arg USA ANCL, autosomal dominant 5
UCL328 p.Leu115Arg USA, French-Canadian Kufs
UCL519 p.Leu116del USA Kufs, autosomal dominant
UCL417 – France Kufs, autosomal dominant
UCL562 – USA Kufs, autosomal dominant 6,7
UCL572 – USA/Italy Kufs, autosomal dominant?
UCL327 – USA Kufs, with ALS in extended family
UCL385 – Belgium Kufs Type A or atypical juvenile NCL, autosomal recessive
UCL403 – France Kufs Type B, autosomal recessive
UCL450 – Poland variant juvenile or ANCL, autosomal recessive
(heterozygous change in CLCN6 already known)
33
UCL472 – Germany variant juvenile or ANCL 34
UCL482 – The Netherlands ANCL
UCL508 – USA Kufs
UCL520 – USA Kufs
UCL522 – USA Kufs
UCL545 – Netherlands Kufs
UCL568 – Austria Kufs
UCL571 – Netherlands Kufs
Diagnosis is provided as reported by referring clinician. In all cases there was no visual failure, and no distinction was made according the mode of inheritance, if
apparent.age-matched controls by using Illumina HumanRef-8v2
Expression BeadChips. This analysis identified a set of
2131 differentially expressed genes, of which 65were local-
ized within candidate regions identified by linkage analysis
(Figure 2B and Table S2). At the same time, we analyzed
gene-expression changes by using gene-enrichment anal-
ysis and found that the identified profiles indicated sig-
nificant dysregulation of spliceosome, upregulation of
many components of respiratory chain complexes, altered
expression of genes active in pathways involved in neuro-
degenerative diseases, and accelerated proteolysis (Table 2
and Figures S1–S7).
To directly identify possible disease-causing mutation(s)
among the candidate genes defined by this combination
of linkage analysis and gene-expression profiling, we per-
formed exome sequencing in individual IV.7. From the
sequencing run we obtained 94.7 M sequencing reads, of
which we were able to map 50.2 M on the human genome
reference sequence. After removing PCR generated dupli-
cate reads (23.6 M), we obtained 26.6 M unique reads,
of which 19.5 M (73.3%) mapped on a targeted exome
sequence and were 92% covered at least once. When
the sequence of the proband was compared to the refer-
ence sequence, 22,617 single nucleotide variants (SNPThe Americquality> 100) and 2604 indels (indel quality> 50) were re-
vealed in the proband, of which 957 (617 SNPs and 340 in-
dels) were novel (e.g., were not present in the dbSNP and
1000 Genomes databases).
We intersected the results of exome sequencing with the
mapping information and the gene-expression changes,
and this analysis illuminated a single gene, DNAJC5,
encoding the protein CSPa, located in the candidate region
on chromosomal region 20q13.33, (DNAJC5 hg19 coor-
dinates chr20:62526518–62565394) and showing a sig-
nificant increase in transcript levels in affected individuals’
leucocytes (Figure 2B), and had a unique heterozy-
gous mutation c.346_348delCTC (p.Leu116del) compat-
ible with autosomal-dominant inheritance of the disease
(Table 3).
CSPa Mutations Segregate with ANCL in Additional
Families
Through sequence analysis of DNAJC5 genomic DNA, we
found consistent segregation of the c.346_348delCTC
mutation with the ANCL phenotype within the Czech
family P1 (Figure 2C). Moreover, among 20 additional
ANCL families and/or simplex cases tested (Table 1), we
identified the same mutation in a previously unreportedan Journal of Human Genetics 89, 241–252, August 12, 2011 245
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Figure 2. Identification of DNAJC5 Mutations
(A) Awhole-genome parametric linkage analysis showing candidate regions reaching the theoretical maximumLOD scores of 2.1 attain-
able in this family on chromosomes 1 (1: 233,697,529–249,250,621), 4 (4: 23,561,661–28,920,119), 15 (15: 39,049,915–61,382,423;
65,139,935–67,296,086; 71,515,415–78,819,152), 20 (20:53,448,624–63,025,520), and 22 (22: 1–21,982,248). All coordinates refer
to hg19.
(B) Gene-expression changes in leucocytes from four affected individuals compared to those of four controls. The logarithm of the
probability that the gene is differentially expressed (log odds) is plotted as a function of the logarithm of the gene-expression fold
change (log fold change) between the patient and control samples. Differentially expressed genes located in the candidate regions
are shown as red dots, and DNAJC5 is specifically indicated. The list of differentially expressed genes located within the linked
regions is, together with log fold changes and corresponding t test values, p-values and adjusted p-values, provided in Supplemental
Data.
(C) Chromatograms of DNAJC5 genomic DNA sequences showing identified heterozygous mutations. (Upper panel) Sequence of an
unaffected individual, (middle panel) sequence showing heterozygous mutation c.346_348delCTC in the proband from family P1,
and (lower panel) sequence showing heterozygous mutation c.344T>G in the proband from family N1.American family, UCL519, and a second heterozygous
mutation (c.344T>G [p.Leu115Arg]) (Figure 1D) segre-
gating with the phenotype in the Dutch family N18 and
the American family UCL5635 and present in a previously
unreported simplex case UCL328. Mutations were found
in all 14 affected individuals (five Czech, six Dutch, and
one in each of the other pedigrees) across these five
families and were absent in all seven unaffected siblings
(two Czech, six Dutch, and one from American family
UCL563) from whom DNA was available for testing. In
addition to this, the identified mutations were absent in
200 control samples of European descent and were not
present in the dbSNP or 1000 Genomes databases.
Haplotypes segregating with ANCL phenotype in Czech
family P1 and Dutch family N1 were obtained from geno-
types generated with Affymetrix GeneChip Mapping 10K246 The American Journal of Human Genetics 89, 241–252, August 1v2.0 arrays and are shown in Figures S8 and S9. For simplex
cases, phased haplotypes could not be obtained. To reveal
whether probands carrying the same mutation might be
distantly related and share a mutation-carrying chromo-
somal segment from a common ancestor, we examined
homozygosity haplotypes across the DNAJC5 genomic
region (Table S3). The c.346_348delCTC (p.Leu116del)
mutations in families P1 and UCL519 are present on two
distinct haplotypes, indicating that these families are prob-
ably not related and that the mutations appeared indepen-
dently. The mutations c.344T>G (p.Leu115Arg) are also
present on two distinct haplotypes, one in UCL328 and
one shared by family N1 and UCL563. This mutation
therefore probably also appeared independently in two
different lineages, but it is possible that families N1 and
UCL563 are identical by descent.2, 2011
Table 2. Functional Annotation of Gene-Expression Changes and KEGG Pathways Defined by Gene-Enrichment Analysis
Term Count % p Value Population Hits Population Total Fold Enrichment FDR
hsa03040: spliceosome 41 2.48 2.3 310 126 5085 2.92 2.9 37
hsa05016: Huntington disease 46 2.78 7.7 38 180 5085 2.29 9.5 35
hsa05010: Alzheimer disease 43 2.60 8.5 38 163 5085 2.37 1.1 34
hsa05012: Parkinson disease 35 2.11 7.0 37 128 5085 2.45 8.7 34
hsa00190: oxidative phosphorylation 35 2.11 1.0 36 130 5085 2.41 1.3 33
hsa00520: amino sugar and nucleotide sugar
metabolism
13 0.79 2.4 33 44 5085 2.65 2.9 30
hsa03050: proteasome 12 0.73 1.2 32 47 5085 2.29 1.4 31
hsa04120: ubiquitin mediated proteolysis 25 1.51 1.5 32 137 5085 1.64 1.7 31
hsa04662: B cell receptor signaling pathway 16 0.97 1.7 32 75 5085 1.91 1.9 31
hsa04621: NOD-like receptor signaling
pathway
14 0.85 1.7 32 62 5085 2.03 1.9 31
hsa00052: galactose metabolism 8 0.48 2.0 32 26 5085 2.76 2.2 31
hsa03010: ribosome 17 1.03 2.9 32 87 5085 1.75 3.0 31Identified Mutations Affect Palmitoylation-
Dependent Sorting and the Amount of CSPa
in Neuronal Cells
Both identified mutations affect conserved dileucine resi-
dues located in the cysteine-string domain implicated in
palmitoylation andmembrane trafficking of CSPa16. UsingTable 3. Exome Sequencing and a List of High-Confidence Novel Codi
Chromosome Position Reference Base Sample Alleles
Fu
Va
Single nucleotide variants
1 235,715,488 C C/T m
1 236,987,512 C C/T sy
1 247,835,885 G C/G sy
15 43,552,700 G G/T m
15 43,900,153 C C/T sy
15 45,028,847 G G/T ut
15 59,500,166 A A/G m
15 65,555,518 A A/G sy
15 66,857,721 C C/T ut
15 75,116,809 G A/G m
20 60,884,827 G A/G sy
22 20,097,643 C C/T ut
22 21,138,487 C C/T sy
Indels
4 25,678,161 TGC TGC co
20 62,562,227 CTC CTC co
All coordinates refer to hg19. SNP qualilty > 100 and indel quality > 50. Only Var
1000 Genomes databases are shown.
The Americin silico analysis, we found that p.Leu115Arg is predicted
to decrease the hydrophobicity of the cysteine-string
domain that is needed for initial binding of CSPa to
the endoplasmic reticulum (ER) (Figure 3A), whereas
p.Leu116del probably affects the efficiency of palmitoyla-
tion of adjacent cysteine residues (Figure 3B). SIFT analysisng Variants Revealed by Exome Sequencing
nction Genome
riation Server Amino Acids Protein Position Gene List
issense ARG.GLN 50/76 GNG4
nonymous none 286/1266 MTR
nonymous none 153/308 OR13G1
issense HIS.ASN 30/721 TGM5
nonymous none 1234/1776 STRC
r-5 none NA TRIM69
issense ILE.VAL 343/382 MYO1E
nonymous none 220/324 PARP16
r-5 none NA LCTL
issense VAL.MET 481/527 LMAN1L
nonymous none 3631/3696 LAMA5
r-3 none NA DGCR8
nonymous none 373/500 SERPIND1
ding none NA SLC34A2
ding none NA DNAJC5
iants located within the linkage candidate regions and not present in dbSNP or
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Figure 3. In Silico Analysis of Properties of the Cysteine-String Domain
(A) p.Leu115Arg mutation decreases the hydrophobicity of this domain, which is needed for initial binding to the ER.
(B) The p.Leu116del mutation decreases the palmitoylation score, that is, the confidence that cysteine residues adjacent to Leu116might
be efficiently palmitoylated.(score ¼ 0.00) predicted that the p.Leu115Arg mutation
affects protein function, and analysis with Polyphen
(overall score ¼ 0.782; sensitivity ¼ 0.85; and specificity ¼
0.93) predicted that it is possibly damaging. No such
predictions can be obtained for the identified deletion
p.Leu116del.
To study an effect of the identified mutations, we tran-
siently expressed wild-type EGFP-tagged CSPa or mutant
protein containing either p.Leu115Arg or p.Leu116del in          wt               p.Leu115Arg         p.Leu116del
CSPα
PDI
merge
EGFP-C
50
40
35
25
A
D
B
p.Leu115Arg
p.Leu115wt
GS28
CSPα
merge
Figure 4. Characterization of Mutated CSPa
(A) Immunofluorescence analysis of transiently expressed EGFP-CSP
tion of wild-type CSPa compared to the diffuse cytoplasmic staining a
ulum represented by PDI and Golgi apparatus represented by Golgi-
(B) Immunoblot analysis of transiently expressed EGFP-CSPa protein
mutant proteins compared the wild-type (wt) protein.
(C) Immunoblot analysis of brain homogenates showing no soluble C
thanol (b-ME)-resistant aggregate (indicated by the asterisk) released
(NCL4) compared to the brain homogenates of the control.
(D) Immunohistochemistry analysis of CSPa in graymatter of the cere
affected individuals compared to the strong CSPa staining in the age
248 The American Journal of Human Genetics 89, 241–252, August 1CAD5 neuronal cells. Using immunofluorescence analysis,
we found wild-type EGFP-CSPa predominantly at the
plasma membrane, whereas both mutated proteins
showed diffuse intracellular staining and abnormal coloc-
alization with markers for the ER and Golgi apparatus
(Figure 4A). In addition, using immunoblot analysis of
transfected cell lysates, we found that both mutated
proteins were less efficiently palmitoylated than the wild-
type protein (Figure 4B).+--+--
++-++-
SPα
50
40
35
25
NCL4 brain control brain
palmitoylated
EGFP-CSPα
nonpalmitoylated
EGFP-CSPα
*palmitoylated
      CSPα
nonpalmitoylated
            CSPα
C
p.Leu116del control
Arg p.Leu116del HAβ-ME
a proteins in CAD5 cells showing prominent membrane localiza-
ndmarked colocalization ofmutated CSPawith endoplasmic retic-
SNARE of 28 kDa (GS28).
s showing higher levels of nonpalmitoylated protein precursors for
SPa and the marked presence of CSPa-containing beta-mercaptoe-
upon hydroxylamine (HA) treatment in the affected individual
bral cortex showing, at a low field, a significant decrease of CSPa in
-matched control.
2, 2011
Figure 5. Brain Immunohistochemistry
(A–C) Detail of the CSPa staining in neuropil in the cerebral cortex that is absent in the individual with mutation p.Leu115Arg (A),
decreased in the individual with mutation p.Leu116del (B), and strong in the age-matched control (C). Note the prominent neuronal
storage, shown by large cell bodies, in both affected individuals.
(D–F) Staining pattern of the synaptic marker synaptobrevin in neuropil in the same regions in the individual with mutation
p.Leu115Arg (D), in the individual with mutation p.Leu116del (E), and in the age-matched control (F).
(G and H) Cerebellar cortex of the case with p.Leu115Arg mutation. Similar to that in the cerebral cortex, CSPa staining is absent (G).
This contrasts with a strong signal for synaptobrevin in the corresponding area in all three cerebellar cortical layers that are preserved
adjacent to areas undergoing neurodegeneration (H).
(I) Strong CSPa staining in a control cerebellum. Note that the CSPa signal in the control (I) as well as the synaptobrevin signal in the
individual with mutation p.Leu115Arg (H) are confined to the well defined synaptic regions (i.e., to the dendrites in the molecular layer,
to the surface of the Purkinje cells, and to the synaptic glomeruli in the granular cell layer). The scale bars represent 25 mm.To correlate these observed effects with in vivo, we
analyzed post-mortem brain specimens by immunoblot-
ting. Although both palmitoylated and nonpalmitoylated
CSPa were present in control brain lysates, we could not
detect any CSPa in brain lysates from a Dutch case (family
N1) with the p.Leu115Arg mutation. However, after chem-
ical depalmitoylation, we detected a chemiluminescence
signal, probably corresponding to an otherwise insoluble
CSPa-containing aggregate, which appeared much stron-
ger in brain lysate from the case, than in the control
(Figure 4C). Using immunohistochemical staining of
CSPa in paraffin-embedded brain sections, we consistently
found an absence of CSPa staining in synaptic regions in
both the cerebral and the cerebellar cortex of individuals
with the p.Leu115Arg mutation and significantly reduced
CSPa staining in the cerebral cortex of individuals with
the p.Leu116del mutation when we compared these indi-
viduals to age-matched controls (Figures 4D and 5).The AmericDiscussion
We carried out linkage mapping, gene-expression analysis,
exome sequencing, and candidate-gene sequencing in
affected individuals from 20 families and/or simplex cases
of European descent suffering from autosomal-dominant
adult-onset neuronal ceroid lipofuscinosis previously re-
ferred to as Parry disease. Using this approach, we
identified in five of these families two recurrent muta-
tions, c.346_348delCTC (p.Leu116del) and c.344T>G
(p.Leu115Arg), inDNAJC5 encodingcysteine-stringprotein
alpha (CSPa). To prove their causality, we performed haplo-
type analysis, which revealed that the mutations had to
appear independently in at least four lineages, and by using
targeted genotyping of seven unaffected siblings and 200
control individuals as well as searching the 1000 Genome
and dbSNP databases, we found that the mutations are
exclusively present in 14 affected individuals.an Journal of Human Genetics 89, 241–252, August 12, 2011 249
CSPa is a highly conserved protein with no amino acid
sequence variant found in humans so far. The identified
mutations affect evolutionary conserved dileucine residues
located in the cysteine-string domain that is implicated in
palmitoylation and membrane targeting of CSPa.15–17
Functional studies in transfected cell lines proved that
these mutations affect palmitoylation and intracellular
location of CSPa and thus decrease the level of the CSPa
protein in the brain of affected individuals.
The molecular mechanisms underlying the dominant
negative effect of the identified mutations on CSPa
amounts in neuronal cells are not clear. It is known that
CSPa forms detergent-resistant dimers18 and that the pres-
ence of these dimers correlates with an inhibition of
synapse formation and synaptic transmission.19 Immuno-
blot analysis of brain lysate from affected individuals
showedCSPa to be exclusively present in such an aggregate
form. It is probable that the presence of mutant protein
catalyzes accelerated aggregation and that the resulting
aggregates will be composed equally of both mutant and
wild-type proteins, and this will result in CSPa depletion.
Another explanation of the dominant negative effect—
nicely compatible with the observed lysosomal storage—
would be a gradual accumulation of nondegradable CSPa
aggregates in the lysosomal system. We followed this lead
experimentally; however, we failed to identify CSPa in
storage lysosomes by using immunohistochemistry anal-
ysis of fixed brain samples as well as in storage granules iso-
lated from affected individuals’ brains by using immuno-
blot analysis (data not shown).
CSPa associates with 70 kDa heat-shock cognate protein
(Hsc70) and small glutamine-rich tetratricopeptide repeat
domain protein (SGT) and forms an enzymatically active
chaperone complex that is tethered to synaptic vesicles
and ensures, in cooperation with other chaperones such
as 40 kDa heat-shock protein (Hsp40),20 90 kDa heat-shock
protein (Hsp90),21 Hsc70 interacting protein (HIP)22 and
Hsp70 organizing protein (HOP),22 correct conformation
of many proteins essential for the functionality of
synapses. It was shown that CSPa deletion causes progres-
sive neurodegeneration and reduced life span in Drosophila
melanogaster23 and knockout mice.24,25 Depletion of CSPa
interferes with SNARE complex formation and has a
profound effect on presynaptic vesicle release and synaptic
function.19,24,26–29 Thus, these CSPamutations might lead
to presynaptic dysfunction, explaining some of the neuro-
logical symptoms observed in affected individuals. In
parallel, dysfunction of the CSPa/Hsc70/SGT chaperone
complex might affect the folding quality of many client
proteins and make them vulnerable to aggregation and
degradation.30Thiscould, in the longterm, lead to lysosomal
accumulationofmisfoldedandproteolysis-resistantproteins
in the form of characteristic ceroid deposits in neurons.
Our finding of neurodegenerative disease caused by mu-
tations inDNAJC5 thus confirms a neuroprotective role for
CSPa in humans and advocates detailed investigation of
CSPa in the NCLs and other neurodegenerative diseases250 The American Journal of Human Genetics 89, 241–252, August 1presenting with neuronal protein aggregation. It is inter-
esting that there is no visual failure in the cases reported
here, in contrast to the rapid loss of vision in mice com-
pletely lacking CSPa function.25
In this study we were able to explain ~25% of ANCL
cases tested, though not all were known to be autosomal-
dominant and some could have been misdiagnosed. Those
families that do not carry mutations in DNAJC5 or other
known NCL genes provide a resource for identification of
further genes whose disruption causes late-onset NCL.
In conclusion, we believe that our work represents an
important step in the genetic dissection of a genetically
heterogeneous group of ANCLs. From a clinical perspec-
tive, and in the absence of specific biochemical markers,
our finding, together with the recent identification of
CLN6 mutations in adult-onset recessive Kufs type A
disease,2 provide essential information allowing efficient
DNA-based testing in families as well as simplex cases
with ANCL presentation.Supplemental Data
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